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Natriuretic Peptide for
Treatment of Heart Failure
A Dying Therapy Reborn?*
Tariq Ahmad, MD, MPH,
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“Yet none of them died, they only changed, were always
reborn, continually had a new face: only time stood
between one face and another.”
—Hermann Hesse (1)
Heart failure (HF) is among the leading causes of death and
morbidity worldwide (2). The development of efficacious
new therapies (such as angiotensin-converting enzyme in-
hibitors and beta-blockers) for HF has generally been tied to
greater understanding of underlying pathophysiology.
Therefore it is not surprising that the essential role played
by natriuretic peptides in maintaining cardiac homeostasis
has prompted significant enthusiasm for the use of natri-
uretic peptides as therapeutics in HF.
See page 2305
Within the context of breakthroughs in HF research, the
discovery of natriuretic peptides was fairly recent. In 1981,
de Bold et al. (3) described an extract from the atria of rats
that had a potent diuretic effect. Subsequent research led to
the characterization of a family of peptides now known as
the natriuretic peptides—atrial natriuretic peptide, B-type
natriuretic peptide (BNP), and C-type natriuretic peptide—
that counterbalance the neurohormonal activation that is a
fundamental aspect of the pathophysiology of HF (4). Of
these, BNP plays a particularly central role in the homeo-
static response to physiological derangements seen in HF
via a rapid release in response to left ventricular (LV)
pressure or volume overload. Given the association of
elevations in BNP (and the biologically inactive amino-
terminal fragment N-terminal proBNP) with hemodynamic
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disclose.perturbations, clinical assessment of these biomarkers has
led to significant improvements in diagnosis and risk strat-
ification of HF patients (5). On the basis of the favorable
hemodynamic consequences of a functioning natriuretic
peptide axis, the natural implication has been that replace-
ment with a biologically active synthetic form would be an
effective treatment for HF.
Nesiritide (recombinant human BNP) was approved in
2001 by the Food and Drug Administration for the treat-
ment of acute HF, a decision based on studies showing
evidence of favorable hemodynamic and clinical effects
(6,7). Initial enthusiasm for this therapy led to its wide-
spread use in the United States, not only for acute HF but
also for intermittent outpatient treatment of chronic HF.
However, there remained a lack of data showing robust
evidence of improvement in clinical outcomes, and ensuing
meta-analyses of publically available studies suggested po-
tentially adverse effects of nesiritide on survival and renal
function (8,9). As detailed in the following text, the subse-
quent conduct of the FUSION II (Follow-up Serial Infu-
sions of Nesiritide) and ASCEND-HF (Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure) studies failed to show substantial clinical
benefits from nesiritide therapy in either chronic or acute
HF, findings that led to diminished enthusiasm for the
potential of BNP as a therapeutic agent in these disorders.
Amidst the current state of uncertainty about the thera-
peutic role for BNP in HF, this issue of the Journal reports
an interesting study by Chen et al. (10) assessing the use of
subcutaneous (SC) BNP in ambulatory patients with
chronic systolic HF. This was a small proof-of-concept
randomized double-blind placebo-controlled study involv-
ing 40 patients that compared 8 weeks of twice daily SC
BNP with placebo. The outcomes of interest were multi-
modality imaging and laboratory parameters: changes in LV
volume and mass via cardiac magnetic resonance imaging
(MRI) (primary outcome), and LV filling pressures mea-
sured via Doppler echo as well as measures of neurohumoral
activation and renal function (secondary outcomes). They
found that SC BNP therapy was associated with significant
reductions in cardiac MRI measurements of systolic and
diastolic volume index and LV mass index but no improve-
ments in LV ejection fraction. The BNP therapy resulted in
echocardiographic evidence of improved LV filling pres-
sures as demonstrated by reductions of the E/e’ ratio and left
atrial volume index. Significant improvements were noted in
the Minnesota Living with Heart Failure score but not in
the 6-min walk test. Renal function did not improve, as
determined by iothalamate clearance calculated glomerular
filtration rate or plasma cystatin C levels. Importantly,
considering the small size of this study, 3 patients in the
BNP arm (3 of 24) developed clinically significant hypoten-
sion and were excluded from the analysis.
Are these findings enough to resuscitate the waning
enthusiasm for the use of synthetic BNP in the treatment of
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context of results from 2 large trials—FUSION II and
ASCEND-HF—testing the use of intravenous (IV) BNP
in chronic and acute HF, respectively. The FUSION II trial
was a randomized, double-blind, placebo-controlled trial of
outpatient serial nesiritide infusion in 911 patients with
stage C/D chronic HF (11). The drug was administered for
4 to 6 h once or twice weekly for 12 weeks. The investiga-
tors found no differences in clinical outcomes between the
nesiritide and placebo groups but a greater incidence of
hypotension with nesiritide. They concluded that there was
“no indication for intermittent outpatient nesiritide infu-
sions in patients with stage C/D HF.” The ASCEND-HF
trial was the largest clinical trial ever performed in acute
HF, randomizing 7,141 patients to either IV nesiritide or
placebo for 24 to 168 h (12). The primary results of the
ASCEND trial showed no reduction in the clinical end-
point of repeat hospital stay for HF or death from any cause.
Once again, there was an excess of hypotension associated
with nesiritide use. The ASCEND-HF authors concluded,
in terms similar to those used by the FUSION II investi-
gators, “nesiritide cannot be recommended for routine use
in the broad population of patients with acute heart failure.”
Therefore, a critical question to be addressed with regard
to the current study is: are there significant differences
between essential elements of the previous large-scale stud-
ies and the current study to warrant additional investigation
of BNP as a therapy for HF? A comparison of key baseline
characteristics, dosing regimens, and side effects between
the current study and ASCEND-HF and FUSION II
studies is shown in Table 1. Because the ASCEND-HF
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ASCEND-HF
Trial dates 2007–2010
Number of patients 7,141
Key inclusion criteria Diagnosis of ADHF along with clinical and
objective measured of HF
Male 66*
Age 67
NYHA functional class II N/A
NYHA functional class III N/A
NYHA functional class IV N/A
Beta-blocker 58
ACE inhibitor or ARB 61
Aldosterone blocker 28
Loop diuretic 95
BNP regimen 2-g/kg bolus followed by 0.01 g/kg/min
Route of administration IV
Duration 24 h–7 days
Incidence of clinically significant
hypotension
7
Clinicaltrials.gov identifier NCT00475852
Values are absolute values, percentages and means, unless otherwise stated. Values have been r
ACE  angiotensin-converting enzyme; ADHF  acute decompensated heart failure; ARB 
ecompensated Heart Failure trial; BNP  B-type natriuretic peptide; Cr  creatinine; FUSION II  Follow
YHA  New York Heart Association functional class; SC  subcutaneous.trial tested short-term infusion of nesiritide in acute HF,
extrapolating these findings to ambulatory HF patients is of
uncertain validity, given the differences in pathophysiol-
ogy between these disease states. A comparison with the
FUSION II study is more relevant: both included patients
with stable chronic HF who were treated with BNP for
similar periods of time (12 and 8 weeks, respectively). With
regard to patient population, the patients enrolled in the
FUSION II study had more severe HF (New York Heart
Association [NYHA] functional class III to IV with recent
HF hospital stay, vs. NYHA functional class II to III),
although there was some degree of overlap, with almost
one-half of the patients in the current study (18 of 40)
classified as having NYHA functional class III symptoms.
Perhaps most importantly, in the FUSION II trial BNP was
administered intravenously once or twice weekly rather than
subcutaneously twice daily. The pharmacokinetic and clin-
ical ramifications of daily SC versus intermittent IV therapy
are unclear. Certainly, for treatment of a chronic condition
such as HF, daily dosing would seem to be the most rational
approach if feasible; it seems unlikely that other proven HF
therapies such as angiotensin-converting enzyme inhibitors
or beta-blockers would be effective if given as a large dose 1
to 2 times/week rather than on a daily basis. The concept of
SC dosing of BNP thus opens the door to daily use in
ambulatory patients, which potentially could allow for lower
doses and lessen vasoactive side effects such as hypotension.
Prior data from the same investigative group have suggested
that low doses of BNP given by IV infusion (approximately
25% to 50% of total daily dose used in current study)
might lead to favorable neurohormonal and anti-
egimenNesiritide Regimen
FUSION II Chronic SC BNP
2004–2006 2003–2008
911 40
recent HF hospital stays, LVEF 40%, and
NYHA III–IV, Cr clearance 60 ml/min
LVEF 35% for at least 2 yrs and
NYHA II–III
71 70
65 66
None 55
47 45
53 None
65 100
59 95
37 20
75 73
-g/kg bolus followed by 0.01 g/kg/min 10 g/kg
IV SC
1–2/week for 12 weeks 2/day for 8 weeks
11.7 12.5
NCT00091520 NCT00252187
to the closest integer. *Median age.
tensin receptor blocker; ASCEND-HF  Acute Study of Clinical Effectiveness of Nesiritide inide R, and
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2315JACC Vol. 60, No. 22, 2012 Ahmad and Felker
December 4, 2012:2313–5 SC BNP Treatment of HFremodeling effects without causing hypotension in the
setting of acute myocardial infarction (13). Whether such
a low dose regimen given subcutaneously would have
biologic effects and avoid the hypotension seen in the
current study is uncertain.
An additional critical question relates to the conundrum
of drug development in HF generally: how reliable are
surrogate variables in early phase studies for predicting
clinical efficacy in larger trials? The authors present com-
pelling data in support of favorable LV remodeling with SC
BNP therapy as measured by cardiac MRI. Ventricular
remodeling has been shown to be central in the progression
of chronic HF, and noninvasive techniques to measure this
process have demonstrated strong correlations with subse-
quent clinical outcomes (14). These findings add credibility
to the notion that SC BNP therapy might have beneficial
cardiovascular effects in chronic HF that deserve further
exploration. As always, the history of drug development in
HF must sound a cautionary note, with multiple examples
of apparently promising approaches that did not pan out in
larger trials (including the initial development of nesiritide
itself) (15).
Where do we go from here? As the authors recognize, the
ongoing development of the concept of SC BNP for
ambulatory HF must grapple with the issue of hypotension,
and ideally a dose or regimen could be identified that would
maintain the anti-fibrotic and remodeling effects without
causing hypotension. Future trials will be needed to refine
dosing and patient selection as well as to provide more
definitive evidence for clinical efficacy. In the novel by
Herman Hesse, Siddhartha experiences various events along
his journey toward enlightenment, reinventing himself in
the process. Whether BNP therapy can be successfully
reincarnated as an “enlightened” therapy for HF therapy
remains to be seen, and further investigation will determine
whether SC administration of BNP might represent the
“middle way” to successful HF therapy.
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